18 Jan 2022 , 03:48 PM
The Board of Lupin at its meeting held on 17 January 2022 has approved the acquisition of a portfolio of brands (including all rights and interests associated with such products) of Anglo-French Drugs & Industries and its associates (subject to approval of their shareholders), to strengthen the Companys portfolio in the Vitamins, Minerals and Supplements and CNS segments.
The transaction entails a lumpsum consideration of about Rs 325 crore including working capital (normalised inventory of three months) amounting to Rs 9 crore (approx.) on a cash and debt-free basis.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
